by Mr C A Clyne (Hammersmith Hospital, London, UK) The natural course of peripheral vascular disease is now fairly well documented. The stable claudicant has become the commonest attender in the vascular out-patient department and bears witness to the fact that the majority of patients never require surgery, many having disseminated vascular disease unsuitable for reconstruction and often affecting other vital organs.
Life-style in the older age groups is often not affected by limited walking distance and the chance of a successful reconstruction with its limited prospect of patency may not justify the small risk involved. Those patients who do progress to rest pain and gangrene or who are disabled by claudication must look to the surgeon for long-term pain relief and limb salvage.
There remains, therefore, a large group of patients who could derive great benefit if drug therapy could improve upon the natural course of their peripheral vascular disease.
The Failure of Vasodilators 'Fluctuations in the severity of claudication represent the natural history of the disease' (Richards 1957) . As a result, many drugs prepared for the treatment of claudication have enjoyed long life due to the difficulty of accurate clinical assessment of their efficacy. In the face of strict clinical trials carried out on apparently stable claudicants and taking into account medication, smoking habits and exercise, no agent emerges as being of clear overall benefit. The standard walking test and the use of the Doppler ultrasound have allowed standardization of testing (Tripolitis et al. 1977) .
The largest group of drugs at present on the market (some of which are enjoying their silver jubilee) are the vasodilators (Goodwin 1952 , Myers 1967 . They fall into three broad groupsthe alpha-adrenergic blockers, the beta-adrenergic stimulants and a further group that work mainly through direct action on the smooth muscle of the vessel wall. Unfortunately, the failure of vasodilators to improve occlusive arterial disease is now well recognized (Coffman & Mannick 1972) .
Boyd has remarked that opening the taps will not alter the rate at which the bath fills if the water is turned off at the mains (Boyd 1956) . Work by Gillespie gave no support for the use of vasodilators in the treatment of claudication as they did not increase blood flow to the calf muscles in patients with occlusive vascular disease (Gillespie 1959 (Gillespie , 1966 . There are at least two reasons for this. Firstly, local metabolites control muscle blood flow and nervous stimuli appear to play a secondary role (Barcroft et al. 1947) . It may be that vasodilator metabolites even block the vasoconstrictor influence of drugs such as noradrenaline (Palmer 1972) , and one must assume that in an ischemic limb the necessary metabolites will have accumulated and be exerting maximal vasodilation.
In addition De Bakey's borrowing-lending hypothesis (De Bakey et al. 1947 ) may even contraindicate vasodilators as they divert blood from ischaemic areas and exaggerate the dramatic fall in ankle pressures seen in the ischamic limb when exercising. It is suggested that collateral maturation may be aided by administration of vasodilators (Westling 1973) , but the rapid development of collaterals following a superficial femoral block, often with almost total alleviation of symptoms, argues strongly in favour of natural development of adequate collaterals wherever possible (Folkow 1967) . Exercise probably has more to offer than medication in achieving these ends (Ericsson et al. 1970 , Schoop 1973 and it seems that '12 ounces of hot tea, to which an ounce of whiskey has been added makes for transient reflex vasodilation comparable with many drugs' (Collens & Wilensky 1953) .
Boyd did concede that these drugs may be of value in mild forms of distal senile obliterative arteritis (Boyd 1956) and Myers also showed that alpha-adrenergic blockade did increase skin blood flow in occlusive arterial disease (Myers et al. 1968 ), but there is no doubt that only a few patients with claudication benefit from the vast annual drug expenditure laid out for peripheral vasodilators.
There has been renewed interest in a group of drugs that possess properties in addition to their vasodilating influence. Naftidrofuryl possesses antiserotonin activity and has a local anesthetic action, eight times greater than procaine (Fontaine et al. 1968 ). More importantly it is claimed to increase the energy available for contraction by improving the muscle levels of phosphocreatinine and adenosine triphosphate (Shaw & Johnson 1975, Elert et al. unpublished) . Given intravenously, it may give relief of rest pain (Greenhalgh et al. personal communication) , and the phlebitis that may occur at the site of infusion (Charlesworth 1977 , Gann 1977 , Woodhouse & Eadie 1977 may well be due to the ward technique used to prepare the solution (Standing et al. 1977) rather than the properties of the drug. Ruckley has recently completed a small double-blind controlled trial of oral naftidrofuryl in claudicants and showed no significant benefit (Ruckley et al. 1978) . A similar but much larger study is at present in progress in the author's department. Cinnarizine and its difluorinated derivative flunarizine is anti-vasoconstrictive (Godfraind et al. 1973 , Van Nueten & Janssen 1973 and can increase digital blood flow at both rest and during ischmmic reactive hyper2mia, in healthy volunteers and in claudicants (Verhaegen et al. 1974 ). This would suggest that steal phenomena are not important with this drug. A number of European trials have shown flunarizine to be superior to cinnarizine and placebo (Schetz etal. unpublished; Staessen 1977) and an evaluation of both of these drugs in a double-blind cross-over trial is also being conducted by the author and co-workers.
Sporadic reports appear in the literature of agents that appear to lessen the symptoms and signs of peripheral vascular disease, usually through unknown pathways. Charlesworth reported the effects of intra-arterial solcoseryl, a protein-free extract of calf blood and showed that it may help to avoid amputation in patients with pre-gangrene (Charlesworth et al. 1975 ). Carlson has reported on the use of prostaglandin E1, showing some improvement in ischmmic limbs in uncontrolled patients (Carlson & Olsson 1976) . In general, however, the drugs so far discussed have proved disappointing and different approaches to increasing blood flow to the extremities have proved more successful.
Alterations ofSystemic BloodPressure
The importance of systemic blood pressure in maintaining peripheral perfusion is not always appreciated and increased life expectancy from control of hypertension may be paid for by increased peripheral ischmmia. Hypotensive agents reduce the pressure available to pump blood to the peripheries and, in the elderly at least, hypotensive therapy in those with disabling peripheral vascular disease should perhaps be more lenient (Caird 1977 , Lancet 1977a . A number of problems are being recognized in association with the use of ,-blockers (Powell & Slater 1958) frequently prescribed for hypertension and following myocardial infarction (Multicentre International Study 1977) .
Propranolol increases peripheral resistance and decreases blood flow to all tissues except the brain (Nies et al. 1973 ) and is well known to exacerbate the symptoms of peripheral vascular disease (Marshall et al. 1976) ; to cause Raynaud's phenomenon (Zacharias et al. 1972 ) and even to lead to peripheral gangrene (Vale et al. 1977) . Scandinavian workers have induced hypertension in the hope of increasing peripheral circulation (Dahn et al. 1967 ). Various agents have been used, of which fluorinated mineral corticoids are the simplest. When these were used in conjunction with sodium supplements, a group of Larsen's patients healed their ulcers and lost their rest pain, with a mean rise in blood pressure of 14 mm Hg (Larsen & Lassen 1973) . It may be unwise to give steroids to this group of patients for any length of time, however, because of the frequent association of peptic ulceration and arteriosclerotic vascular disease (Bouhoutsos et al. 1972) , although this did not create problems in Larsen's investigation.
Angiotensin infusion has achieved similar results but, as would be expected, cardiopulmonary complications make this a risky form of therapy (Hansteen & Lorentsen 1973) .
Hemorrheology
Better understanding of the physiology of blood flow has led to more exciting developments in the medical approach to the treatment of peripheral vascular disease. In the early 1960s, the importance of the viscosity/hwmatocrit relationship and its effect on blood flow was emphasized (Wells & Merrill 1962) and the role of viscosity in myocardial infarction was examined (Burch & Depasquale 1962) . Since then, haemorrheology has developed enormously. The peripheral vascular effects of polycythemia vera have long been recognized (Edwards & Cooley 1970) and even mild degrees of polycythamia at the time of vascular surgery are associated with thrombotic problems (Bouhoutsos et al. 1974 ). Blood flow in this group of patients can be improved by phlebotomy (Cranley et al. 1963) , marrow depression by 32P or simple dilution using low molecular weight dextran or Hartman's solution (Dormandy 1971) . Cerebral and peripheral vascular symptomatology will be improved by treatment of polycythmmia and lowering of whole blood viscosity (Thomas et al. 1977) .
However, it is in the serum fraction of the blood that abnormalities more commonly accessible to treatment have been detected (Merrill et al. 1963) . High levels of fibrinogen have been found in association with symptoms of peripheral vascular disease (Dormandy et al. 1973) . One action of clofibrate is to lower plasma fibrinogen (Cotton et al. 1963 ) and Dormandy treated 64 patients with this drug for an average of one year and found benefit in those patients with an initially raised plasma fibrinogen and increased blood viscosity . 'Controlled defibrination' may also be achieved by the use of derivatives of snake venom, ancrod and defibrase, which convert fibrinogen to pseudofibrin which is then removed from the blood (Holleman & Coen 1970 , Ehrly 1976 . Ancrod, given subcutaneously, caused a fall in plasma fibrinogen and whole blood viscosity which iesults in objective evidence of increased limb blood flow (Dormandy et al. 1977 ). Paraproteiniemia can also give rise to increased plasma and whole blood viscosity and high levels of globulins, for example, should be sought in patients with exaggerated symptomatology and relatively normal arteries (McGrath etal. 1973) .
Increased red cell rigidity is another factor impeding blood flow in patients with peripheral vascular disease (Reid et al. 1976) , and oxpentifylline is said to reduce this and to improve flow (Ehrly 1975 , Buzzi et al. 1976 ). Jarrett and his colleagues have shown this agent to increase fibrinolysis and this may be of value in small vessel occlusive disease (Jarrett P E M et al. 1977) .
Whatever its mode of action, a number of trials show that oxpentifylline may relieve claudication, improve walking distance and promote healing of ulceration.
Modifying the Pathophysiology ofAtheroma Experimental evidence exists suggesting that the pathophysiological process of atherosclerosis itself may be modified by various agents. Animal work has revealed that the early development of the atherosclerotic plaque may be suppressed by cortisone and other anti-inflammatory drugs (Bailey & Butler 1973) and it has been suggested that aspirin protects rheumatoid arthritis sufferers from atheroma (Wood 1972) .
Hyperlipidmmia is a major risk factor in vascular disease (Greenhalgh et al. 1971, Royal College of Physicians and the British Cardiac Society Joint Working Party 1976) and cholesterollowering diets may play a part in its prevention (Lewis 1976) . Although agents such as clofibrate (Grundy et al. 1972) , nicotinic acid (Fitzgerald et al. 1964 ) and cholestyramine (Lancet 1968) lower serum cholesterol, there is yet no conclusive evidence that this improves prognosis for life or limb, and a large American trial is at present in progress involving dietary control and cholestyramine. Hyperlipidemic patients with the more lethal Frederickson type II hyperbetalipoproteinzmia, which is more commonly associated with ischamic heart disease, may be less prone to peripheral vascular involvement which is more frequent in types III, IV and V (Slack 1969) .
The rarity of peripheral vascular disease in females prior to the menopause suggests that estrogens offer protection from atherosclerosis, and in women subjected to oophorectomy there is an increased liability to the development of arterial disease (Sznajderman & Oliver 1963) .
Exogenously administered cestrogens in the form of the contraceptive pill were associated with increased ischamic heart disease, but this is probably due to thromboembolic causes and not increased atheroma (Mann & Inman 1975) . Oral contraceptives may also cause an increase in blood cholesterol (Stoke & Wynn 1971) . Oestrogens given to men with carcinoma of the prostate were shown to reduce the incidence of atheroma by Rivin & Dimitroff (1954) and London et al. (1961) but the Veterans Administration Trial showed there to be an increase in cardiovascular deaths (Blackerd et al. 1970 ) although these were not thought to be due to increased atheroma (Hanash et al. 1969) . There is even evidence that prophylactic supplementation of the maternal diet with vitamin B, may protect against atheroma in the offspring (Levene & Murray 1977) .
Once the atheromatous lesion is established, it may still be possible to encourage regression (Armstrong 1976) . Experimental evidence shows that diet and cestrogens are effective in chickens (Horlick & Katz 1949 , Pick et al. 1952 ). Barndt has recently reported regression of femoral artery atheroma in a group of hyperlipoproteinemic patients using diet combined with clofibrate, neomycin sulphate and hypotensive agents (Barndt et al. 1977) . Assessment was based on femoral angiography.
There is little evidence that long-term anticoagulation protects against progression of 'non-embolic' atherosclerotic disease, but it may decrease the frequency of occlusions (Selvaag 1962 , Tillgren 1965 . One series from Germany did show a deterioration in the angiographic appearances of a group of controls when compared with an anticoagulated group (Burkhalter et al. 1974 ) and the controversy that surrounds the status of anticoagulant therapy in the prevention of myocardial infarction has its parallel in limb ischemia. Anticoagulation will, of course, protect the vessels distal to an ulcerated atheromatous plaque (Barker 1955), or patients with arteriomegaly (Thomas 1971 , Vollmar et al. 1976 from repeated embolization, but the place for antiplatelet agents in these situations is still unclear.
In most reported series of peripheral vascular disease up to one-third of patients are diabetic and although the diabetes/atherosclerosis link is not clear (Keen 1976) , there is some evidence to support the hypothesis that well-controlled levels of blood sugar do delay the development of vascular complications (Cahill et al. 1976 , Knowles 1965 . However, a large American series designed to evaluate the long-term cardiovascular effects of various hypoglycemic agents showed that tolbutamide (University Group Diabetes Program 1970) and phenformin (University Group Diabetes Program 1975) were associated with higher mortality rates than diet alone in controlling patients. Other studies do not confirm this (Jarrett J R et al. 1977) and in the insulin-treated group, those patients with poor blood glucose control appeared to fare no worse, as regards vascular problems, than the wellcontrolled group (University Group Diabetes Program 1971) .
Finally, to compound the problem, some studies suggest that raised levels of insulin may play an important role in the development of atheroma (Stout & Vallance-Owen 1969 , Lancet 1977b ) and insulin could possibly be detrimental in this respect when given to patients. However, few clinicians doubt the wisdom of adequate diabetic control in the immediate management of lesions such as the diabetic foot (Goodman et al. 1976 ).
The Effects ofAlcohol and Cigarettes The commonest drugs taken by patients with developing or established vascular disease are alcohol and tobacco. Alcohol causes vasodilation of the peripheries in normal limbs but probably suffers from the same short-comings as other vasodilators in the ischaemic limb with rest pain (Gillespie 1967) . There is no evidence to suggest that alcohol alone either causes or protects against arteriosclerosis obliterans, but it may cause hypertriglycerid&mia (Castelli et al. 1977 , Gebbie & Prior 1967 . It is an important source of extra calories leading to obesity, is often linked with increased cigarette smoking and its withdrawal may predispose to thromboembolism (Haselagar & Vreeken 1977) .
The risk of intermittent claudication increases with the intensity of the smoking habit (Kannel & Shurtleff 1973) , but blood levels of carboxyhamoglobin may provide a better indication of the risk of atherosclerosis than the smoking habit alone . The almost total lack of non-smokers presenting with claudication and the risk to the limb of continuing to smoke (Juergens et al. 1960 , Mathieson et al. 1970 ) is the evidence provided daily to the clinician. Even cigarettes with 'low-tar' content still cause vasoconstriction, vascular disease and lung cancer (Hammond et al. 1976 ) and it remains to be seen whether the latest 'safe' cigarette will prove popular and effective. Finally, reduced arterial oxygen saturation in smokers taking strenuous exercise (Zwi et al. 1964 ) will exacerbate symptoms of reduced blood flow. There is therefore no case for the continued self-administration of nicotine which alone represents a very high risk factor in peripheral vascular disease. And although thromboangiitis obliterans is now a controversial disease entity (Larson & Silvette 1975) its close association with smoking is still quoted (British MedicalJournal 1977) .
Diseases other than Arteriosclerosis Obliterans
There remains a group of vascular diseases whose origins are often obscure, but where treatment is frequently of benefit. There is little doubt that Takayasu's arteritis benefits from maintenance steroid therapy (Nako 1967 , Fraga & Mintz 1972 , but few Western doctors see many cases. Stenoses and occlusions that cause symptoms are probably not relieved and require surgical correction during remission of the arteritis.
Raynaud's phenomenon is often improved by simple vasodilators. Holti has examined digital blood flow following administration of allegedly vasoactive drugs (Holti (1978a) and obtained clinical benefit in a double-blind trial using oral tetranicotinylfructose (Holti et al. 1971 ). Significantly higher fingertip temperatures and prolonged cooling periods necessary to induce Raynaud's phenomenon were shown using this drug.
Naftidrofuryl also may be of benefit in Raynaud's phenomenon but the effect may not be immediate and the drug may have to be given for a few days before benefit is seen (Holti 1978b) . Nilsen is at present undertaking a double-blind cross-over study of oral naftidrofuryl in Bristol, but gastric side-effects may cause problems in this group ofpatients (Holti, personal communication) .
Raynaud's phenomenon secondary to such conditions as polycythcmia (Edwards & Cooley 1970) or paraproteinwmia may respond dramatically to correction of the primary disease (McGrath et al. 1973) , but in association with scleroderma, presents a greater challenge. Surgery has little to offer to this group of patients, giving little if any relief. Although much disputed, the results of intra-arterial reserpine may give some benefit adequate to allow healing of ischmmic tissues (Lancet 1970) . Injections may be given directly into the brachial artery or through a selective catheter at the time of an arteriogram and frequent injections may be required (Tindall et al. 1974 ). Nilsen has given repeated injections (in an open study) at intervals of 10-90 days and has confirmed the clinical benefit with studies of cutaneous blood flow (Nilsen, unpublished and personal communication).
Infusion of low molecular weight dextran at varying intervals provides a simple and safe method of treating ischemic skin disorders. A good clinical response can be obtained in scleroderma, but less benefit is seen in patients whose primary disease is arteriosclerosis obliterans (Holti 1972 ). The addition of naftidrofuryl to each infusion may provide additional benefit.
Peacock's regime (Peacock 1960 ) seemed to give encouraging early results but does not appear to have gained wide acceptance, possibly due to the hazards of using drugs such as triiodothyronine and phenoxybenzamine. It has probably now beensupersededbythe otheragents describedabove.
Conclusion
The place of surgery in peripheral vascular disease is now well established and can offer those patients with localized lesions a high chance of success with an acceptable low morbidity and mortality (Jamieson & Clyne 1977) . There is no panacea for those patients not offered surgery. However, the opportunity exists for the clinician to regard the patient with an ischemic limb or digit as suffering from a generalized illness and to investigate him accordingly. It is particularly in the fields of hemorrheology and lipid metabolism that drugs may prove able to alter the natural course of peripheral vascular disease to the benefit of the patient.
